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Abstract  
Context: Despite support for active surveillance (AS) as a first treatment choice for men with low-
risk prostate cancer (PC), this strategy is largely underutilized.  
Objective: To systematically review barriers and facilitators to selecting and adhering to AS for low-
risk PC.    
Evidence Acquisition: We searched PsychINFO, PubMed, Medline 2000-now, Embase, CINAHL 
and Cochrane Central databases between 2002-2017 using the Preferred Reporting Items for 
Systematic Review and Meta-analysis (PRISMA) statement. The Purpose, Respondents, Explanation, 
Findings and Significance (PREFS) and STROBE quality criteria were applied. Forty-seven studies 
were identified. 
Evidence Synthesis: Key themes emerged as factors influencing both choice and adherence to AS: 
(1) patient- and tumour factors (age, co-morbidities, knowledge, education, socioeconomic status, 
family history, grade, tumour volume, fear of progression/side-effects); (2) family and social support; 
(3) provider (specialty, communication, attitudes); (4) healthcare organisation (geography, type of 
practice) and (5) health policy (guidelines, year, awareness). 
Conclusion: Many factors influence men’s choice and adherence to AS on multiple levels. It is 
important to learn from the experience of other chronic health conditions as well as from 
institutions/countries that are making significant headway in appropriately recruiting men to AS 
protocols; through standardised patient information, clinician education and nationally agreed 
guidelines, to ultimately decrease heterogeneity in AS practice.  
Patient Summary: We reviewed the scientific literature for factors affecting men’s choice and 
adherence to AS for low-risk PC. Our findings suggest that the use of AS could be increased by 
addressing a variety of factors such as information, psychosocial support, clinician education and 
standardised guidelines.   
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Introduction  
Prostate cancer (PC) accounts for 400,000 new cancer cases in Europe [1]  and 160,000 in the 
US [2] annually. Rapid uptake of prostate specific antigen (PSA) testing and better diagnostic 
procedures have led to a significant stage migration with earlier diagnosis of localized, low-risk PC 
(LRPC), ranging from 10% - 80% of all men diagnosed with PC worldwide [3-5]. A large proportion 
of these men do not require immediate radical treatment, but can be monitored using blood tests, 
digital rectal examination, prostate biopsy and/or multi-parametric magnetic resonance imaging 
(MRI) - an approach known as active surveillance (AS) [5].  
While there are no universally agreed upon selection criteria for AS, the authors of a recent 
review of  currently used guidelines worldwide agreed on the following criteria, consistent with the 
definition of very LRPC: clinical stage T1c-T2a; PSA <10 ng/mL; biopsy Gleason score 6; maximum 
1 or 2 positive biopsy cores; and/or maximum 50% of cores with cancer [6].  
Large cohort studies (appendix 1) reporting over the last 5 years have shown little physical 
morbidity and low PC specific mortality whilst on AS: 0.1% to 5.7% over 10 – 15 years [7, 8], 
observations which have recently contributed to an increased uptake of this management strategy [5, 
9].  
AS uptake continues to vary across countries, practices and amongst physicians [10]. This 
was most noticeable in the US CaPSURE database, which reported a sharp rise in the uptake of AS, 
from 10% over the past two decades to 40% in 2010-2013 [5] and the Swedish National Prostate 
Cancer Register which noted a rise from 40% to 74% between 2009 and 2014 [11]. In Australia, 
where the healthcare culture is fairly evenly split between private and public systems, a 25% overall 
recruitment to AS was recorded by the Victorian PC Registry during the period 2008-2012 [12]. 
However, in Sweden, where healthcare is delivered largely by the public sector, the proportion of men 
selecting AS was significantly higher (80-90% of eligible men) [11]. Understanding the drivers for 
this variation in practice is essential.  
In cohort studies reporting on AS adherence, a large proportion of men continue to drop out 
of AS, despite no evidence of disease progression (Appendix 1). Much research has focused on the 
influence of anxiety and depression on adherence. Cancer Research UK describes depression as an 
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established response to a diagnosis of cancer, unrelated to stage or severity [13]. However, in PC the 
risk of moderate to severe depression (requiring treatment) has been reported as relatively low in 
comparison to other tumour groups, at 5% [14].   
There is thus a need to identify and understand the barriers and facilitators to AS. This would 
then provide means for future research themes to study interventions aimed at increasing both the 
uptake of and adherence to AS. The purpose of this paper is therefore to systematically evaluate the 
literature for factors affecting choice and adherence to AS as a PC management strategy for LRPC. 
 
Evidence acquisition 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines [15].  
2.1 Search strategy 
Studies published between 2002 (when AS was first described in the literature [16]and December 
2017 were identified through a systematic search of electronic databases (PsychINFO, PubMed, 
Medline 2000-now, Embase, CINAHL and Cochrane Library) (Figure 1).  The search strategy 
focused on the use of keyword search terms to identify studies based on PC AS: Prostate cancer OR 
prostatic neoplasm, active surveillance OR watchful waiting, facilitators OR barriers, treatment 
adherence OR treatment compliance, treatment OR therapy OR therapeutics and decision making. 
The full search strategy is identified in Figure 2. References were also searched for eligible 
publications. 
2.2 Study eligibility and selection  
Eligible studies for inclusion in the final analysis were those that evaluated choice and/or 
adherence to AS rather than watchful waiting (WW). Although there are similarities between choice 
of AS and WW, they are conceptually different management strategies (AS is a strategy employed to 
monitor a patient where there is intention to offer radical treatment with curative intent when/if 
required, WW implies no intention to offer curative treatment). Hence, studies where AS and WW 
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sub-groups were combined were excluded to reduce bias.   
We considered studies eligible if they were original articles with a qualitative or quantitative 
design generating data on decision-making in LRPC when AS was considered as a primary treatment 
option. Eleven studies were excluded on the basis of poor study quality or mixed WW/AS sub-group 
[17], as were qualitative studies that failed to state that saturation of information had been reached, 
usually ≥20 participants. Studies including at least 20 participants is a general guideline in qualitative 
research to reach data saturation [18]. One study that fell beneath this threshold was included as 
information saturation was demonstrated.  
Cohort/Registry studies were included when they were multi-institutional and included >500 
patients to reduce the associated risk of bias in small sample sizes and increase the external validity 
and generalisability. Studies reporting on AS adherence also included ≥2 years of follow-up.  
 
2.3 Data quality   
Qualitative and mixed methodology studies were evaluated for quality using The Purpose, 
Respondents, Explanation, Findings and Significance (PREFS) quality checklist [17]. This checklist 
was previously developed by Bridges et al. for assessing quality of reports in systematic reviews of 
literature on patient preferences and comprises questions regarding five aspects of each study: 
purpose (P), respondents (R), explanation (E), findings (F), and significance (S). The complete 
PREFS checklist is shown in Table 1. Appendix 3 outlines the quality questions. A quality score was 
calculated by adding one point for each “yes” answer on the PREFS checklist, with a maximum 
potential score of 5. Papers were categorized in a similar way to that reported by Joy et al [17]: 
standard gamble (SG, i.e. HRQoL’s) – 17 papers; contingent evaluation (CO, i.e. survey) – 14 papers; 
stated preference other (SPO, i.e. monetary value or choices or ratings) – 3 papers; qualitative (i.e. 
interviews) – 13 papers and 3 papers with mixed methodology. 
The mean PREFS quality score was 3.46 (SD 0.54), and the scores ranged from 2 to 5. The mean 
quality scores were 3.15 (SD 0.55) in studies with qualitative methods, 3.33 (SD 0.57) in studies with 
SPO methods, 3.76 (SD 0.44) in studies with CO methods, 3.58 (SD 0.51) in studies with SG methods 
and 3 (SD 0) in studies with mixed methodology. 46 studies explicitly stated that the purpose (P 
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domain) of the study was to evaluate factors effecting choice or adherence to AS, and 31 studies 
included all respondents in the evaluation of findings (F domain). There was more variability among 
the studies in satisfying the R, E, and S domains of the PREFS checklist, demonstrating that many 
reports lacked details regarding whether responders were similar to non-responders and failed to 
include statistical tests to evaluate results where possible. 
The included cohort/registry epidemiology papers were assessed for strength of evidence. Although 
no quality assessment tool completely fitted the purpose of this review, assessments were made using 
a modified Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) 
checklist [19] (Table 2). The following items were assessed: number of participants, variables (clear 
explanation of all outcomes, exposures, potential confounders and effect modifiers), data source 
(details given of measurement), bias (effort made to address potential sources of bias), statistical 
methodology (description of methods, missing data addressed, sensitivity analysis performed), 
descriptive data (characteristics of individuals given: demographic, clinical and social) and limitations 
(generalisability addressed, cautious interpretation). In each of the seven categories 1 point was 
assigned to each positive response, giving a possible total score of 12.  
The mean quality score was 8.78 (SD 1.8). The scores ranged from 5 to 11. All studies 
included outcome variables, a full description of statistical methodology, clinical data and limitations. 
The highest level of variability was found in relation to bias, missing data and sensitivity analysis. 
Five papers scored ≥10.  
 
3.0 Evidence synthesis and extraction 
We identified 1,049 unique citations; of these 901 were excluded as review articles, commentaries 
or narratives. Full-text screening was carried out on 148 articles, of which 85 were excluded, 
rendering 64 articles included for synthesis. Given the heterogeneous study designs, no statistical 
comparisons were made.  
This mixed-methods systematic review uses a modified version of The Joanna Briggs Institute – 
Methodology for JBI Mixed Methods Systematic reviews (Integrated approach) [20]. Joanna Briggs 
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Institute integrated methodology combines both qualitative and quantitative date into a single mixed 
methods synthesis [20]. A meta-aggregation of data is presented using a Bayesian approach, whereby 
all data was codified into themes and then presented in a meta-aggregation This approach generates 
summative statements of the evidence to equally inform the topic in a mutually compatible format 
[21], as seen in Table 2.  The six themes identified were: cancer characteristics, patient, family and 
social support, provider, healthcare organization/practice and health policy.  
Three authors (NK, MVH and SC) independently screened all titles and abstracts. The resulting 
reference list was compiled for full-text screening and data extraction. The final reference list was 
screened and agreed by all authors. A data abstraction form was developed for both qualitative and 
quantitative studies, based on review of the first articles of each type from among the selected papers. 
One author (NK) extracted data onto a spreadsheet, which was checked by two other authors (SC and 
MVH). Data abstraction was performed separately by two reviewers (NK and SC or MVH). Data 
extraction included: publication year, authors, journal name, title, study design, setting, population, 
eligibility criteria for participants, data collection method, response rate, and outcomes (Table 1). The 
review of findings/themes was open-ended with no pre-specified coding system, with intent to 
describe the primary conclusions of the authors.  
3.1  Study design of included studies  
Table 3 summarises the 64 included studies. 37 studies took place in North America, 20 in 
Europe, 5 in Australia, one compared America to Ireland and one was a worldwide study. The total 
number of study participants was 452,4560, ranging from 7 to 189,768 in each study. The average age 
at diagnosis across the studies was 65 years.   
The assessments were reported between 2007 and 2017. The studies consisted of 13 surveys, 12 
qualitative interviews/focus groups, 12 cohort/registry studies, 2 content analysis and 1 intervention 
study and 7 mixed method studies. 17 studies reported Health related quality of life (HRQoL) and/or 
psychological assessment data using validated questionnaires/tools (Appendix 2).  
Some overlap in studies was noted with 8 of 64 studies reporting on factors influencing both 
active surveillance choice and adherence.  
8 
 
4.0  Results 
This review has been split into 2 sections: Barriers and facilitators to AS selection and to AS 
adherence. These have been further synthesised and demonstrate influence on six different levels: 
cancer characteristics, patient factors, family and social support, provider, organisation and practice, 
and health policy. The sections below discuss facilitators and barriers according to these levels. 
 
4.1 Barriers and facilitators to AS selection 
 
4.1.1 Cancer characteristics  
Facilitators:  
Nine studies described how cancer characteristics such as PSA, number of positive cores, 
Gleason score and tumour volume, influenced the selection of patients for AS.  A low Gleason score 
and a low PSA value were identified as facilitators of AS in five of them [11, 22-25]. Five studies [22, 
23, 26-28] also suggested that tumour volume played an influential role in AS selection, with lower 
volume associated with higher levels of AS selection. 
Barriers:  
The UK-based Prostate Testing for Cancer and Treatment (ProtecT) study, US based 
CEASAR Study and Swedish NCPR (National Prostate Cancer Register) [29-31] found that men with 
higher PSA’s and tumour staging were disinclined to choose AS when diagnosed.  
 
4.1.2 Patient level 
Facilitators: 
Eight studies [26, 28, 32-36] indicated that older men were more likely to choose AS than 
younger men, but were in general less engaged in the decision-making process than younger men 
[32]. Co-morbidity was featured in seven studies [11, 22, 24, 33-35, 37]. The SEER registry reviews 
[34, 37], the US National Cancer Database [38],  Swedish studies [11, 24], a US Multi-disciplinary 
clinic study [22] based in Boston and the Michigan MUSIC Study [23] showed an association 
between a higher Charlson co-morbidity index and choice of AS. Orom et al. [33], however, found 
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that the presence of cardiovascular disease was associated with a greater likelihood of choosing 
radiation over AS. Both Orom’s [39] and Parikh’s [36] studies suggested that men with more years of 
education were more willing to opt for AS, however another study suggested higher education was a 
barrier to AS choice [24]. 
Six studies [25, 32, 40-43] suggested that fear of side effects (in particular erectile 
dysfunction and incontinence) following radical treatment was a strong determinant of AS. Ehdaie 
[44] found that significantly more men opted for AS (12%) if during treatment counselling they had 
pro-actively been encouraged not to ignore potential harms of treatment. 
 
Barriers: 
Nine studies showed that younger men were less likely to choose AS. Three studies [32, 33, 
45] found men younger than 60 years old were less likely to choose AS. One comment from a patient 
in a qualitative interview was “choosing AS would be irresponsible, ridiculous even - at my age (aged 
53)”.  
Other studies reported patient-related factors including ethnicity and family history of PC. 
Aizers et al [22] suggested that family history of PC increased the likelihood of an early drop out from 
AS; this is consistent with Volks’ [40] interview findings that twice as many patients who opted for 
primary curative treatment had a relative with PC, compared to patients who opted for AS. Xu’s study 
[27] showed that black men, as compared to white, were less likely to choose radical treatment, and 
specifically surgery, due to the high risk of adverse effects. In contrast, Oroms’ survey [33] suggested 
a racial difference in the use of AS, with a higher proportion of black men choosing radiotherapy over 
AS.  
The association between the level of education and AS is inconsistent: the Prostate Cancer 
Database Sweden (PCBaSe)  [24] suggested that a higher level of education precipitates lower use of 
AS in the low-risk PC group  (26% of men versus, 39% with a mid-level education and 35% with a 
lower education level). 
The psychological burden of AS in respect to the associated repeat testing during AS [46, 47], 
as well as the morbidity from repeat prostate biopsies [25], were also linked to reduced uptake of AS. 
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Wade [48, 49] found that men who were well informed about prostate biopsy were less likely to 
refuse repeat biopsy. This is important to acknowledge in the context of AS where monitoring 
includes regular re-biopsy. However, several studies have described the process of repeat testing on 
AS as a reassuring process [40, 42, 46].  
 
4.1.3 Family and social support 
Facilitators:  
In all of the interview studies, men on AS described justifying their decision to others as one 
of the most difficult aspects of the decision-making process. Both Xu and Goh [45, 50] reported that 
AS referred to as “no treatment” was often more challenging for the spouse and children to understand 
than for the patient. Successful reassurance and education of the family was highlighted as a key 
facilitator to patients choosing and adhering to AS [40, 45, 46].  
Four interview studies from the US, UK and Canada [25, 32, 40, 46], showed that “avoidance 
of treatment side effects”, “more convenient for lifestyle” and a “combination of reasons” were 
recurring themes explaining the choice of AS. The UK study [25] also showed that men were equally 
as satisfied with their decision to undertake AS as those who had undergone radical treatment two 
years later. 
 
Barriers:  
Pressure from family and friends has been found to be high at the point of diagnosis, many of 
whom urged curative treatment [45, 47]. To give an example, in qualitative interviews performed by 
Xu et al [45] one man stated that he initially preferred AS plus nutrition supplements to avoid 
treatment-related side effects, but that his family pressured him to choose RP and, as a compromise, 
he finally chose radiation. In another example, one man stated that he felt unspoken pressure from his 
family to choose curative treatment.  
Perception and acceptance of AS requires careful management. Orom’s 2017 survey [33] 
described that high levels of distress at the time of diagnosis and at the time of the treatment decision 
were a predictor for choosing radical prostatectomy over AS. In contrast, Xu et al [27]  found that 
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black men were more likely to report higher levels of “cancer worry”, but that their perception of the 
negative effects of radical treatment often led to fewer men choosing radical treatment.  
4.1.4 Healthcare provider level 
Facilitators:  
Eleven of the reviewed studies suggested that the clinician heavily influences the decision-
making process [26, 32, 33, 41, 44, 46, 47, 50-53]. Scherr, Liu and Davison all found that the 
diagnosing urologist was most influential clinician associated with AS choice [26, 32, 53]. Orom’s 
2017 survey [51] found that a poor relationship between patient and clinician was mentioned by only 
1% of men who were appropriately recommended AS for LRPC, but by as many as 53% of men who 
were recommended a definitive treatment only.  
Loeb et al [52] found that clinicians were concerned about the burden of intensive monitoring 
and that they might miss disease progression. However, both Orom [51] and Loeb [52] found that 
shared decision-making would address this.  
Health literacy is defined as an “individual’s capacity to access, understand, communicate, 
evaluate, utilize, and make decisions based on health information” [54]. Therefore, provision and 
access to relevant information is a consistent theme in both increasing the uptake of and adherence to 
AS. Mishra at al [47] described the views of patients and their families in internet conversations over 
a 10-year period; they found that access to unbiased information was associated with more patients 
opting for AS. Four other studies [32, 40, 42, 46] reported similar results.  Goh et al [50] found that 
men who perceived they were receiving consistent information felt more in control of their decision-
making and experienced a greater degree of satisfaction and certainty in choosing AS. Three other 
studies concluded that access to educational resources, in addition to professional and peer support 
(supported self-management), optimised the treatment selection process and empowered men “to take 
control” of their diagnosis and of their choices thereafter [42, 47, 55]. However, in contrast Taylor and 
colleagues [28] found that even when patients had access to information and support, men who 
choose AS were less likely to access these resources than those men choosing radical treatment.  
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A US multidisciplinary clinic study [22] found that AS selection was further facilitated 
through a multi-disciplinary provider approach, removing the bias of treatment recommendation 
which is often associated with clinicians that carry out a particular treatment. Patients receiving 
treatment-counselling from two or more specialist clinicians were twice as likely to opt for AS, than 
radical treatment (43% versus 22%). This was further confirmed and described during semi-structured 
interviews by Lyons et al [56]. 
Ehdaie [44] further found that a systematic approach for communicating the merits of AS 
using appropriate framing techniques, increased the proportion of patients selecting AS (69% pre- 
intervention to 81% afterwards). Equating to a 30% relative reduction in unnecessary curative 
treatment. 
Several studies have also reported that by slowing down the treatment decision-making 
process providers might influence an increase in the proportion of men choosing AS [46, 47, 56]. 
Volk and colleagues [40] found significance in men viewing their cancer as “low-risk” as it offered an 
opportunity to postpone treatment allowing sufficient time for technological advances in treatment. 
When asked if men chose AS as a holding mechanism only or as a long-term solution, patients fitted 
into two groups: those who concluded selection of AS meant avoidance of side effects and those that 
felt AS gave them time to make a treatment decision.  
 
Barriers:  
Conversely, the clinician’s influence has also been listed as a barrier for choice of AS. 
Mishras review of the changing trends in internet conversations over a 10-year period suggested that 
patients were increasingly receptive to considering AS, but many questioned if physicians could 
provide an unbiased treatment recommendation [47]. This concern was also articulated in four of the 
interview studies [40, 45, 46, 50] where patients expressed concern about the possibility of clinician 
bias at the time of consultation, with many of them recalling that they were either not offered AS as 
an option or the patients perception of AS was “doing nothing”. Scherr and colleagues [53] reviewed 
patient-physician interactions over the period that treatment decisions were made and found that 
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physicians were heavily influenced by age and Gleason score, but not by the value that patients put on  
treatment outcomes e.g. sexual dysfunction.  
Both Parikh and colleagues [36] used the US National Cancer Database (NCDB) to review 
40,839 men with low-risk prostate cancer in relation to a number of variables. They found that the 
barriers to AS included living a longer distance from the provider facility, and those men diagnosed 
by a physician working outside of an academic or research facility. 
4.1.5  Healthcare organisation and practice level 
Facilitators and Barriers: 
Many narrative reviews of AS highlight differences in AS protocols among healthcare 
providers, health care systems and also within individual countries [11, 12, 23, 26]. For example, the 
MUSIC group found that the use of AS varied substantially between different urology practices in the 
state of Michigan, ranging from 27-80% of eligible patients [23, 26]. This variability could simply be 
attributed to the recommendation of the clinician, but two studies [40, 47] focused on access to 
clinical expertise and technology, suggesting that patients felt that they were only offered AS where 
there was availability of imaging facilities and expert clinicians to deliver the AS protocol. A similar 
diagnostic practice related influence was also observed in the Michigan MUSIC study [23, 26]. 
 
Type of healthcare system as a barrier to AS was mentioned in one study [52] which found that 
the US system placed limitations on a clinician’s ability to recommend AS (although did not find that 
this was due to financial incentives) and carry out the necessary regular re-testing associated with AS. 
However, Parikh and colleagues [36] found that analysis of the NCDB suggested higher uptake of AS 
in the uninsured.  
 
4.1.6  Health policy level 
Facilitators and barriers: 
In 2006-2007, Mishra et al [47] reported that, patient and clinician attitudes towards AS 
(calculated numerically as a “sentiment-index” in the content in internet conversations) were at their 
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lowest, with both judging AS  “not safe” and “should only be offered to older patients”. By 2009, 
Mishra et al found the internet sentiment-index was high, meaning there was a more positive attitude 
towards AS.  Reasons for this included a 2009 American Urology Association endorsement for AS 
[57] and a 2010 publication of a large scale AS cohort [58] reporting a very low mortality rate over 
intermediate follow-up. In Sweden, Loeb and colleagues [11] also found that AS uptake (2009-2014) 
significantly increased and hypothesised that this was largely due to National Guidelines 
recommending AS.  
4.2.  Barriers and facilitators to AS adherence  
4.2.1.  Cancer characteristics 
Facilitators: 
Several population-based studies reported on cancer characteristics in relation to AS 
adherence. The UK-based Prostate Testing for Cancer and Treatment (ProtecT) study, US based 
CEASAR Study and Swedish NCPR (National Prostate Cancer Register)  [29-31] found that men 
with lower PSA’s and tumour staging were more inclined to adhere to AS.  
Barriers:  
The Swedish NPCR study [29] reported that the <65-year age group and those with higher 
education levels (<9 years full-time education) were significantly less likely to continue AS than the 
older and less educated groups. These findings have been replicated in qualitative studies such as 
those carried out by Lang and O’Callaghan [31, 46], which found that younger men with higher 
educational level found the notion of long-term AS, i.e.  “doing nothing”, less tolerable than the 
associated morbidity of radical treatment. The Swedish National Prostate Cancer Registry (NPCR) 
study [29] also reported that out of those men who discontinued AS, 52% did so because of PSA 
progression and 24% due to biopsy progression. 
 4.2.2 Patient level  
Facilitators: 
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Patient perceived experience of AS featured in 3 studies. Goh [50] analysed the experience of 
AS in 34 men and found that those who viewed their experience with cancer as having a positive 
impact on their lives were better able to manage the uncertainty of AS, and felt more in control of 
their decision-making, and during AS. Oliffe [59] found that men reporting a higher level of positivity 
in the face of their cancer diagnosis (attributed to consistency in information and support) were less 
likely to exhibit decision-making conflict related to the perceived effectiveness of their treatment plan 
and therefore may be more inclined to remain on AS. These studies suggest that careful patient 
selection is important for both treatment choice and adherence [50, 59]. Volk et al [40] found that 
men described the process of AS as an organized, supportive process of regular monitoring.  
Four of the seven HRQoL studies had no control group [60-63]. Wilcox and Jeldres [62, 64] 
found no change in HRQoL before or after entry into an AS programme. Parker [63] found that as age 
and body mass index increased, HRQoL decreased over time. Both Parker and Bellardita [60, 63] 
found that >5 months after diagnosis and commencement of AS, HRQoL improved. 
Bellardita [60] also noted that men with a partner and men who had >18 biopsy cores taken at 
diagnosis were more likely to have a good HRQoL on AS. Hegarty [61] compared HRQoL between 
men on AS in Ireland and the US: general HRQoL and vitality was lower in the US group – which 
they reported was likely due to differences in health-care expectations.  
The six studies that included control subjects of either men with no cancer [65] or those 
undergoing radical treatment [66-69] or both [70], showed no statistical differences in HRQoL 
between the control subjects and men on AS. The Finnish section of the PC Research International: 
Active Surveillance (PRIAS) study [65] found better than average HRQoL (as defined by the RAND-
36 Questionnaire) than in the general Finnish male population, both immediately following entry into 
AS and 1 year later. Vanagas [66] and Venderbos [67] both reported better HRQoL in men on AS 
than in men who had undergone radical treatment with respect to physical, emotional and social 
scales. Donovan and colleagues reviewed patient-reported outcomes comparing monitoring to surgery 
and radiotherapy as part of the ProtecT trial [68]. The monitoring cohort consistently did better in 
respect to three of the four domains; erectile, urinary and bowel function, however there was no 
significant difference in HRQoL amongst the three treatment groups. Smith [70] found similar 
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HRQoL scores across AS and treatment groups. Chen and colleagues [69] reported similar results 
recently from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study 
(NC ProCESS) where contemporary PC treatments were compared to AS in respect to HRQoL. 
However, after 24 months it was notable that QoL scores were not clinically meaningfully different 
between the treatment and AS groups. 
When measuring the anxiety associated with long-term surveillance adherence, the majority 
of studies included in this review suggested that anxiety reduced [65, 66] or remained the same over 
time [14, 60, 62, 71-74], with no observed impact on long-term adherence. 
In the recently published ProtecT study, depression was reported in only 6% of the 545 men 
allocated to active monitoring over a period of 10 years, suggesting that depression and anxiety do not 
increase significantly whilst on AS [30, 75]. 
A number of studies have shown that emotional distress is relatively high in men at the time 
of their PC diagnosis [33, 76]. However, anxiety in men on long-term AS has been generally reported 
as favourably low. A 2015 systematic review [77] reported no overall difference between levels of 
anxiety following diagnosis of LRPC and during AS, which was reported as between 4-15%. In fact, 
more studies have suggested that anxiety in men on AS reduces [65, 66, 71] or remains the same over 
time [14, 60, 62, 71-74].  
Barriers: 
The Swedish National Prostate Cancer Registry study (NPCR) [29] reported that out of those 
men who discontinued AS, 20% stopped due to patient preference alone. The US based CEASAR 
Study [31], which included men from five Surveillance, Epidemiology and End Results (SEER) 
catchment areas, and the Cancer of the Prostate Strategic Urologic Research Endevour (CaPSURE) 
database [31] found that 8-23% of men converted to curative treatment for reasons of personal 
preference rather than disease progression.  
These findings were further explored in two large qualitative studies exploring men’s survival 
expectations as a result of selecting treatment for low risk PC. Xu  [78] reviewed men’s perceptions of 
the likely benefits and harms of radical treatment versus no treatment (AS). This was calculated in the 
form of patient perceived life expectancy (LE). At the time of the survey, two thirds of the 229 men 
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had started or completed treatment. Of these, 30% in the AS group expected to live <5 years. This 
was in contrast to in the treatment group where >95% of patients estimated their LE to be >5 years. 
Kendel [79] also reviewed perceptions of the risk of death from PC between matched patients who 
had undergone AS or radical prostatectomy (RP). Men who had undergone RP estimated the risk of 
dying from PC associated with AS to an average of 51%, at least a 10-fold overestimation of the true 
risk. They believed that their 10-year risk of dying from PC after a RP was only one third of the risk 
of AS (18% - also a substantial overestimation). Both studies thus suggest that patients’ perception of 
survival is a barrier to both AS selection and long-term adherence.  
Although some studies suggested that “fear of cancer progression” may be a limiting factor to 
choosing AS [59, 80-82], none have convincingly shown that this contributes to a significant number 
of men opting out of AS without documented clinical progression (Venderbos [82] found this was 
5%). Both Davison [73] and Parker [63] found that the degree of “fear of progression” did not change 
significantly over a period of AS.  
 
4.2.2.  Family and social support 
Facilitators: 
Four studies highlighted that successful reassurance and education of the family was a key facilitator 
to patients both in choosing and adhering to AS [40, 45, 46]. Loeb’s  [83] qualitative focus group and 
interview study found that social support and interaction (support groups, online forums, support for 
spouse and family) was of particular importance in AS adherence. An AS support group for both 
family and men with PC was a particularly strong recommendation. Mader [42] interviewed 15 men 
following their decision for AS and found strong correlation between AS adherence and social 
support, including spouse, extended family and experiences of others.  Anandadas and colleagues [84]  
further demonstrated that men were equally as satisfied with their decision to undertake AS as those 
who had undergone radical treatment two years later. 
 
Barriers: 
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Pressure from family and friends is reportedly high at the point of diagnosis, many of whom 
urge curative treatment [45, 47]. The experiences of friends and family members with cancer (often 
not PC) are consistently reported as a significant pressure in men on AS [45, 47]. Berger [85] noted 
men reported leaving AS and pursuing treatment to limit their loved ones' worry, or in reaction to the 
fear of cancer expressed by their family. Partner anxiety was also documented by Seiler [86], who 
compared levels of anxiety and depression between men on AS and their partner. Anxiety scores were 
much lower in the men than in their partners. The CaPSURE database [31] found that 16% of men 
converted to curative treatment on the basis of “spousal encouragement”. 
 
4.2.3  Healthcare provider 
 
Facilitators:  
Seven studies identified facilitators to AS adherence including; education, self-management 
techniques, healthcare professional and peer support in the furtherance of increasing AS adherence. 
Loebs [83] combination of focus groups and semi-structured interviews found six themes relating to 
the facilitation of AS adherence. Five of these were consistent with healthcare provider 
responsibilities in the form of informational needs; (1) information on PC (biopsy features, 
prognosis), (2) information on AS (testing protocol, difference between AS and WW), (3) information 
on complimentary options (diet, lifestyle), (4) variety of resources (source, format), (5) integrity of 
information (trusted source, secure, multidisciplinary). Oliffe [59] found that self-management 
strategies helped men cope with some of the long-term uncertainty of AS, whilst ‘The Prostate Cancer 
Lifestyle Trial’ based on lifestyle modifications, including exercise and attention to stress 
management, demonstrated an improved treatment-free survival for men on AS [87].   Goh [50] found 
that men who perceived that they were receiving useful, consistent information were more satisfied 
with AS and therefore more likely to continue on AS. Kinsella and colleagues [88] found that AS 
classes significantly improved long-term adherence to AS, as did consistency of personnel to support 
and inform patients as found in the UK based ProtecT Trial [89].  Interventions relating to peer 
support have also demonstrated a significant improvement in the quality of life of men with any stage 
of PC [88, 89].  
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Barriers: 
The ability of healthcare providers to deliver long-term support to patients on AS was 
highlighted in several studies [85, 90, 91].  Men leaving AS describe a number un-met supportive care 
needs [85]. These include lack of education and clarity concerning the correct time to pursue 
treatment, triggers for treatment both from a patient and relative perspective.    
Two studies [90, 91] specifically focused on the influence of support groups.  These noted 
either no effect or even a negative effect on long-term AS adherence, possibly due to the group 
consisting of a mix of survivors, i.e. those who had undergone radical treatment and those on AS [91]. 
Chapple [90] found support groups were of no help to men on AS, with one man reporting that he felt 
he “had to defend himself “in the support group for choosing AS.  
Mishra [47] concluded that there was a lack of consistent and reliable information available to 
men during long-term AS.  
4.2.4  Healthcare organisation and practice level 
Facilitators and Barriers: 
 
Differences in surveillance strategies have also demonstrated an association with adherence 
both in a positive and negative respect (Appendix 1). These contemporary cohort studies all include a 
strategy of repeat biopsy as part of a robust AS protocol. Two studies found that prostate biopsy was 
associated with significant morbidity and AS adherence could therefore be influenced by 
frequency/requirement to re-biopsy.  The ProBE (The effects of Prostate Biopsy) study nested within 
ProtecT, assessed patient response to prostate biopsy and indicated that 25% of men who had 
undergone prostate biopsy were dis-inclined to undergo subsequent biopsies [48], whilst a study by 
Bokhorst [92]  as part of the PRIAS study suggested that complications following prostate biopsy 
were not uncommon (20% of men), and after complication men were less likely to accept repeat 
biopsy.  
20 
 
However, in two interview-based studies that took place in the US [40, 46], men gave a 
consistent description of AS, viewing it as a reassuring, organised and supportive process despite 
invasive testing. 
4.2.5  Health policy level 
Facilitators and Barriers:  
 
 AS protocols in respect to patient selection, safe monitoring and triggers for intervention vary 
between study cohorts, healthcare systems and countries, which makes it difficult to produce a 
coherent, consistent clinical guidance document. In Sweden, Loeb and colleagues [11] found that AS 
uptake and adherence (2009-2014) significantly increased and hypothesised that this was largely due 
to clear National Guidelines recommending AS. Likewise the PRIAS study [93] suggested improved 
compliance and adherence as part of an official AS programme. 
 
4.3 Results synthesis 
The barriers and facilitators to AS choice and adherence were categorised into six levels as 
part of this review: cancer characteristics, patient, family and tumour characteristics, patient factors, 
family and social support, provider, organisation and practice, and health policy, these are 
summarised in table 4. These barriers and facilitators varied in both strength of association and level 
of evidence, and are described in Figure 3. The barriers and facilitators identified as most influential 
over the six levels are symbolised as circles, with larger circles representing a greater degree of 
evidence as supported by this review.   
 
5.0 Discussion 
A demonstrable rise in the use of AS has been noted over a short timeframe, however there are 
significant differences between individual healthcare providers as seen in the US CaPSURE Database 
[5] and Swedish PcBaSe [11]. Local guidelines, national policy, patient education, supportive care, 
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and medicolegal factors may be important factors driving this variation [10, 12] and therefore these 
issues require greater consideration and management if we are to better facilitate AS. 
Studies focusing on men’s perception of risk as a barrier to choosing AS show that men 
continue to grossly overestimate the risk of dying from LRPC whilst on AS [25, 32, 45, 47]. 
Moreover, understanding the implications of HRQoL and psychological factors on the decision to 
both choose and adhere to AS requires further multi-dimensional assessment and interpretation. 
Clinicians and patient groups actively encourage the increasing responsibility that PC patients are 
taking for self-directed management and informed decision-making [87, 94]. Such patient 
empowerment has positive psychological effects on cancer patients in general and should be explored 
in the specific context of AS [87, 94].  
These elements have been explored in the context of the chronic disease setting, which one 
could argue relates well to a diagnosis of LRPC that may never require curative treatment. A 
systematic review of general health screening and treatment decision making in the chronic disease 
setting [95] found that clinicians employing a process of ‘motivational interviewing’ consistently 
improved patients knowledge, perception of risk, and increased confidence in decision making. 
Motivational interviewing is specifically designed to help patients identify and resolve ambivalence 
about changing their behaviour by exploring personal perspectives and perceived barriers [96]. It 
employs a four-step guiding style (engaging, focusing, evoking, and planning) to foster a constructive 
clinician-patient relationship. Joosten [97] found that motivational interviewing improved the patients’ 
ability to self-manage and increased adherence to chronic-disease management plans. 
Although there is currently no published experience of motivational interviewing in AS, a 
recent systematic review in other cancer patients [98] found that it was useful for eliciting lifestyle 
behavioural changes, decreasing cancer related anxiety and encouraging supported self-management. 
This also supports that argument that men on AS experience a similar physical and psychological 
burden to people living with other chronic conditions [99], such as asthma and diabetes [100-104], for 
whom quality of life relies on adherence to a treatment plan with the aim to optimize disease control, 
maintain quality of life, prevent unnecessary escalation of treatment.   
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Another systematic review [100] outlining the merits of supportive self-management in 
chronic disease adherence suggested that there are core components of support and that their 
implementation requires a holistic approach, which intervenes at the level of the patient, the health 
care professional and the organisation, much in the same way as identified in this review of AS: 
(1) provision of education about the long-term condition (LTC) 
(2) psychological strategies to support adjustment to the LTC 
(3) practical support tailored to the LTC  (e.g.  support around activities of daily living for 
disabling conditions and action plans in conditions subject to marked exacerbations)  
(4) social support 
(5) lifestyle modifications (e.g. diet and exercise) 
 
Our current systematic review highlights the need for improved validated methods for patient 
and physician education to facilitate the uptake of AS among men with LRPC. Moreover, studies 
suggesting that clinician’s bias may influence the treatment decision-making process [26, 32, 33, 41, 
46, 47, 50, 51] suggest that educational efforts aimed at clinicians and frameworks for how they 
deliver the information on treatment options [44] are important for increasing the acceptance of AS. 
Education, appropriate information and support aimed at both the patient and their family have long 
been recognised as important in the management of chronic conditions (77,78), with studies 
demonstrating an increase in adherence to treatment plans where these have been established.  
In addition, many chronic disease studies have successfully explored strategies to reduce 
healthcare inequalities in chronic health conditions [103, 105, 106]. This has been achieved through 
the standardisation of education and training to both clinicians and patients, development of 
educational materials and decision aids, as well as creation of specialist centres for chronic conditions. 
To date, one study has replicated this in the context of AS.  Formica and colleagues [107] reported 
that decision aids in combination with standardised patient education packages achieved a three-fold 
increase in AS acceptance.  
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 Several AS papers suggested that National guidelines could have a significant impact on 
selection and adherence to AS [11, 47, 93]. This has been replicated in the chronic disease setting 
[104, 108]. In diabetes management, the introduction of the Dutch Guidelines increased clinician 
adherence by 60%, suggesting that guidelines are reassuring for both patients and clinicians [108]. 
The current discordance in AS management makes internationally ratified guidelines a priority, and 
efforts such as those employed by the GAP3 consortium (Movember) [109], which has established 
active communication and collaboration among research groups worldwide, are likely to change this. 
GAP3 aims to reach international consensus on the definitions and terms used in AS through analysis 
of a global database including >14,000 patients [109].  
The requirement for continuous monitoring in AS has been described as both a barrier and 
facilitator. In chronic disease management, it gave rise to early developments in telehealth with some 
studies suggesting that easy-to-learn applications can improve adherence, lessen disease impact, 
accelerate behaviour change to improve outcomes and increase patient and partner confidence during 
remote monitoring [110, 111]. AS monitoring protocols are currently undergoing rationalisation, with 
more frequent imaging and less biopsies. Although we found no reports of the use of mobile health 
applications in the AS setting and only one small pilot of an internet based application specifically 
aimed at managing uncertainty in AS [112], the change in the way we survey patients could lend itself 
to the introduction of robust remote monitoring using this technology. 
The role of social media in choice and adherence to AS has not yet been explored, however, 
on-line social networks have changed the way we communicate and provide new ways to engage 
patients. Twitter and Facebook groups established to engage cancer patients offer easy access to peer 
support and have been associated with less stress, anxiety and depression (86-87) and in the chronic 
disease setting, Kirwan [113] found that combining [114] on-line applications and social networking 
significantly increased diabetic glycaemic control in comparison to the control group.  
A combination of these core elements is critical to ensuring positive experience and benefit of 
living with LRPC on AS.  
Advances in PC management including the use of multi-parametric MRI, and more 
sophisticated prostate biopsy strategies in both diagnostics and surveillance programmes could also 
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change the level of reassurance in AS.  Alongside this, a recent systematic review focused on the 
development of genomic profiling suggests that combining genome-wide association studies (GWAS) 
data with gene expression and structural rearrangements and risk alleles could provide a new basis for 
developing a prognostication tool to guide therapy for men with LRPC [114].  
 
6.0  Limitations  
This review is limited as a mixed methodology paper. The included studies were heterogeneous and 
therefore a meta-analysis was not possible. This type of systematic review relies on a reasonable 
number of included studies for strength, however the weighting of individual studies needs to be 
adjusted based on the varying levels of evidence and methodological quality of the included studies. 
However, this has been represented using the PREFs quality checklist and a modified STROBE 
checklist, which was reviewed by the three reviewers independently. 
Of the papers reviewed, some did not distinguish entirely between AS and WW and therefore older 
age and co-morbidity as facilitators to AS may be inaccurate in 2018. Another limitation concerns the 
generalizability. More than 50% of studies were North American, and this healthcare system may not 
be generalizable to other countries.  
 
7.0 Conclusion 
 Many factors influence men’s choice and adherence to AS, such as the clinician’s 
attitudes, family and social support and patient education. The clear recommendations of this review 
include agreed international guidelines on AS and the introduction of a multidisciplinary management 
strategy with psychological support to facilitate the AS. Current clinical practice at centres with high 
AS uptake may provide insight of the changes required to ultimately decrease the overtreatment of PC 
worldwide, whilst experience gathered in the chronic disease setting such as the introduction of 
supportive self-management, social media interventions and motivational interviewing, could form 
the blueprint for future AS programmes to increase both choice of and adherence to AS in LRPC.  
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